BMS-351
BMS-351 (compound 18) is a potent, oral active, nonsteroidal CYP17A1 lyase inhibitor with the IC50 values of 19 nM and 4 nM aganist human CYP17A1 and cynomolgus monkeys CYP17A1, respectively. BMS-351 can be used for the study of castration-resistant prostate cancer[1].
Product Specifications
CAS Number
1370001-71-0
UNSPSC
12352005
Target
Cytochrome P450
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bms-351.html
Smiles
FC(F)(CN1C=NC2=C1C=CC=C2C3=C(C)C=CN=C3)F
Molecular Formula
C15H12F3N3
Molecular Weight
291.27
References & Citations
[1]Huang A, et al. Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer. ACS Med Chem Lett. 2015;7 (1) :40-45. Published 2015 Dec 2.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1145236-01 0.02 mg (E-Coli)
Recombinant Geobacter uraniireducens Glutamate-1-semialdehyde 2,1-aminomutase (hemL)
Sign In for Pricing
View Details